Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin and magnesium sulfate in neonatal hypoxic-ischemic encephalopathy
PACTR201812814507775Not yet recruiting
- Sponsor
- Ezenwa Beatrice
- Start
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Trial of erythropoietin and magnesium sulfate in hypoxic-ischemic encephalopathy (HIE) and asphyxia neonatorum (2 arms), sponsored by Ezenwa Beatrice. Primary endpoints: Survival at discharge or death within the first two years of life and Neurodevelopmental impairment. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
erythropoietinmagnesium sulfate
03
Conditions
hypoxic-ischemic encephalopathy (HIE)asphyxia neonatorum
Beyond the preview
Go deeper on PACTR201812814507775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201812814507775.